Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113106 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Tingxuan Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Postdoctoral Program for Innovative Talents, National Natural Science Foundation of China.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) represents a prevalent malignancy of the urinary system. Despite the integration of immune checkpoint inhibitors (ICIs) into the treatment paradigm for advanced RCC, resistance to immunotherapy has emerged as a pivotal determinant impacting the clinical outlook of ccRCC. Accumulating evidence underscores the pivotal role of immune evasion-related genes and pathways in enabling tumor escape from host immune surveillance, consequently influencing patients' responsiveness to immunotherapy. Nonetheless, the clinical relevance of immune evasion-related genes in ccRCC patients undergoing immunotherapy remains inadequately understood. In this study, we aggregated RNA sequencing and clinical data from ccRCC patients across three cohorts: the Cancer Genome Atlas (TCGA), CheckMate cohorts, and the JAVELIN Renal 101 trial. Leveraging a curated immune evasion-related gene set from Lawson et al., we employed the LASSO algorithm and Cox regression analysis to identify eight genes (LPAR6, RGS5, NFYC, PCDH17, CENPW, CNOT8, FOXO3, SNRPB) significantly associated with immune therapy prognosis (HR, 3.57; 95 % CI, 2.38-5.35; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
- The School of Basic Medical Sciences, Fudan University, Shanghai, China.
- Department of Urology, Guangzhou Twelfth People's Hospital, Guangzhou, China.
- Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: zhangzhl@s…
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: helir@s…
Förderung
- National Postdoctoral Program for Innovative Talents
- National Natural Science Foundation of China
Zitieren
APA
Huang, T., Peng, Y., Liu, R., Ma, B., Chen, J., Wei, W., Zhong, W., Liu, Y., Guo, S., Han, H., Zhou, F., Zhang, Z., He, L., & Dong, P. (2024). Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113106
Vancouver
Huang T, Peng Y, Liu R, Ma B, Chen J, Wei W, et al. Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113106
BibTeX
@article{Huang2024,
author = {Huang, Tingxuan and Peng, Yulu and Liu, Ruiqi and Ma, Binglei and Chen, Junlin and Wei, Wensu and Zhong, Weifeng and Liu, Yang and Guo, Shengjie and Han, Hui and Zhou, Fangjian and Zhang, Zhiling and He, Liru and Dong, Pei},
title = {Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113106}
}
EUVIMED